BGLC 8-K
BioNexus Gene Lab Corp (BGLC)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of Company as specified in its charter) |
|
| |||
(State or other jurisdiction |
| (Commission |
| (IRS Employer |
of Incorporation) |
| File Number) |
| Identification Number) |
(Address of principal executive offices)
Phone: +1 (
(Company’s Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security Holders
On December 24, 2025, BioNexus Gene Lab Corp. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
The matters voted upon at the Annual Meeting and the final voting results were as follows:
Proposal 1 — Election of Directors
Each of the following nominees was elected to serve as a director of the Company to hold office until the Company’s next annual meeting of stockholders or until his or her successor is duly elected and qualified.
Nominee |
| Votes For |
|
| Votes Against |
|
| Abstentions |
| |||
Su-Leng Tan Lee |
|
| 972,902.8 |
|
|
| 4,485.5 |
|
|
| 300 |
|
Muhammad Azrul bin Abdul Hamid |
|
| 972,902.8 |
|
|
| 4,485.5 |
|
|
| 300 |
|
Jook Yuen Low |
|
| 971,641.8 |
|
|
| 4,485.5 |
|
|
| 1,561 |
|
Chee Keong Yap |
|
| 972,902.8 |
|
|
| 4,485.5 |
|
|
| 300 |
|
Proposal 2 — Approval of the 2025 Equity Incentive Plan
The Company’s 2025 Equity Incentive Plan was approved.
Votes For |
|
| Votes Against |
|
| Abstentions |
| |||||
|
|
| 966,759.8 |
|
|
| 10,628.5 |
|
|
| 300 |
|
Proposal 3 — Ratification of Independent Registered Public Accounting Firm
The appointment of JP Centurion & Partners PLT as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified.
|
| Votes For |
|
| Votes Against |
|
| Abstentions |
| |||
|
|
| 973,284.3 |
|
|
| 3,402.5 |
|
|
| 1,001.5 |
|
Proposal 4 — Approval of Adjournment Proposal
The proposal to approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies was approved.
|
| Votes For |
|
| Votes Against |
|
| Abstentions |
| |||
|
|
| 966,489.3 |
|
|
| 9,647.5 |
|
|
| 1,551.5 |
|
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BioNexus Gene Lab Corp.
| /s/ Su-Leng Tan Lee |
|
By: | Su-Leng Tan Lee |
|
| Chief Executive Officer |
|
|
|
|
Date: | December 30, 2025 |
|
3 |